ESMO24 GI Review: LEAP-012, TOPGEAR, and EMERALD

At ESMO 2024, Zev Wainberg, MD, from the University of California, Los Angeles, reviews the ESMO data on gastrointestinal malignancies and notes that it is now unclear who should receive radiation before surgery. He discusses trials in gastric cancer, hepatocellular carcinoma, and pancreatic cancer.

Dr. Wainberg is optimistic about the future of the tricky endpoint that progression-free survival in hepatocellular carcinoma is known to be. He sees much compelling early-phase data for the drugs with data presented at ESMO.